

EXAMINER'S AMENDMENT

An Examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to Applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it **MUST** be submitted no later than the payment of the issue fee.

Authorization for this Examiner's amendment was given in a telephone interview with Jacob Weintraub (Reg. No. 56,469) on Wednesday, May 12, 2010.

The following amendments have been authorized:

IN THE CLAIMS:

Please amend Claim 26 in the following manner:

---Claim 26 (Currently Amended): A method of treating prostate cancer which comprises administering an effective amount for treating prostate cancer of *N*-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, to a warm blooded animal in need of treatment of prostate cancer.---

Please amend Claim 27 in the following manner:

---Claim 27 (Currently Amended): A method for reducing abnormal proliferation in a prostate cancer cell or inducing differentiation of a prostate cancer cell which comprises administering an effective amount for reducing abnormal proliferation in a prostate cancer cell or inducing differentiation of a prostate cancer cell of *N*-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, to a warm blooded animal in need of reduction of abnormal proliferation of a prostate cancer cell or in need of inducing differentiation of a prostate cancer cell.---

Please amend Claim 28 in the following manner:

---Claim 28 (Currently Amended): A method of inducing apoptosis in a prostate cancer cell which comprises administering an effective amount for inducing apoptosis in a prostate cancer cell of *N*-

Art Unit: 1614

(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, to a warm blooded animal in need of inducing apoptosis in a prostate cancer cell.---

Claims 26-28, 41-43 and 51-53 are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Leslie A. Royds whose telephone number is (571)-272-6096. The examiner can normally be reached on Monday-Friday (9:00 AM-5:30 PM).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin H. Marschel can be reached on (571)-272-0718. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Leslie A. Royds/
Primary Examiner, Art Unit 1614

May 13, 2010